Literature DB >> 2941046

Photodynamic therapy of ascites tumours within the peritoneal cavity.

Z Tochner, J B Mitchell, P Smith, F Harrington, E Glatstein, D Russo, A Russo.   

Abstract

A murine ascites tumour was treated with intraperitoneal haematoporphyrin derivative (HPD) and laser light (10mW, 514nm, Argon laser). HPD was given intraperitoneally 2 hours before 16 minute laser treatment. Uptake studies 2 hours after HPD injection showed 5-12 fold greater concentration of HPD in tumour cells than in 4 different normal tissues. A total of four HPD/laser treatments, given at 2 day intervals, resulted in 100% complete response; the cure rate was 85%. This study illustrates the effective use of intraperitoneal photodynamic therapy and opens the possibility of exploring different sensitizers, excitation wavelengths, and delivery systems in the treatment of human ascites tumours.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941046      PMCID： PMC2001401          DOI： 10.1038/bjc.1986.126

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  14 in total

1.  Quantitative determination of porphyrin uptake by tumor tissue following parenteral administration.

Authors:  J WINKELMAN; D S RASMUSSEN-TAXDAL
Journal:  Bull Johns Hopkins Hosp       Date:  1960-10

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 3.  Hematoporphyrin and HPD: photophysics, photochemistry and phototherapy.

Authors:  D Kessel
Journal:  Photochem Photobiol       Date:  1984-06       Impact factor: 3.421

4.  Hematoporphyrin derivative in the diagnosis and treatment of lung cancer.

Authors:  R G Vincent; T J Dougherty; U Rao; D R Doiron
Journal:  Adv Exp Med Biol       Date:  1983       Impact factor: 2.622

5.  Intraperitoneal chemotherapy.

Authors:  R F Ozols; C E Myers; R C Young
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

6.  Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder.

Authors:  J F Kelly; M E Snell
Journal:  J Urol       Date:  1976-02       Impact factor: 7.450

7.  Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

Authors:  R F Ozols; G Y Locker; J H Doroshow; K R Grotzinger; C E Myers; R I Fisher; R C Young
Journal:  Cancer Treat Rep       Date:  1979-02

8.  Photoradiation therapy for the treatment of malignant tumors.

Authors:  T J Dougherty; J E Kaufman; A Goldfarb; K R Weishaupt; D Boyle; A Mittleman
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

9.  Detection and localization of In situ carcinoma of the bladder with hematoporphyrin derivative.

Authors:  R C Benson; G M Farrow; J H Kinsey; D A Cortese; H Zincke; D C Utz
Journal:  Mayo Clin Proc       Date:  1982-09       Impact factor: 7.616

10.  Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer.

Authors:  Y Hayata; H Kato; C Konaka; J Ono; N Takizawa
Journal:  Chest       Date:  1982-03       Impact factor: 9.410
View more
  8 in total

1.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

2.  An Orthotopic Murine Model of Peritoneal Carcinomatosis of Ovarian Origin for Intraoperative PDT.

Authors:  Thierry Michy; Claire Bernard; Jean-Luc Coll; Véronique Josserand
Journal:  Methods Mol Biol       Date:  2022

3.  Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model.

Authors:  B A Goff; J Blake; M P Bamberg; T Hasan
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

4.  Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer.

Authors:  L R Duska; M R Hamblin; M P Bamberg; T Hasan
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC.

Authors:  R Hornung; M K Fehr; J Monti-Frayne; B J Tromberg; M W Berns; Y Tadir
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma.

Authors:  R B Veenhuizen; J P Marijnissen; P Kenemans; M C Ruevekamp-Helmers; L W 't Mannetje; T J Helmerhorst; F A Stewart
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

7.  Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.

Authors:  B A Goff; U Hermanto; J Rumbaugh; J Blake; M Bamberg; T Hasan
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

8.  Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light.

Authors:  T H Foster; S L Gibson; R F Raubertas
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.